NEW YORK--(BUSINESS WIRE)--
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Teva Pharmaceutical Industries Limited (“Teva”) (NYSE:TEVA) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/TEVA-Request-Form-1686. There is no cost or obligation to you.
On August 2, 2016, Teva completed its acquisition of Allergan plc’s generics business, Actavis Generis. Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. Then on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge.
To learn more about the investigation of Teva contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TEVA-Request-Form-1686.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006131/en/
